[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2024103400A1 - Composé polycyclique utilisé en tant qu'activateur de gpr75, composition pharmaceutique le comprenant et son utilisation - Google Patents

Composé polycyclique utilisé en tant qu'activateur de gpr75, composition pharmaceutique le comprenant et son utilisation Download PDF

Info

Publication number
WO2024103400A1
WO2024103400A1 PCT/CN2022/132928 CN2022132928W WO2024103400A1 WO 2024103400 A1 WO2024103400 A1 WO 2024103400A1 CN 2022132928 W CN2022132928 W CN 2022132928W WO 2024103400 A1 WO2024103400 A1 WO 2024103400A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkylene
cycloalkyl
membered heterocycloalkyl
halogen
Prior art date
Application number
PCT/CN2022/132928
Other languages
English (en)
Chinese (zh)
Inventor
张丰盈
杨阳
陈庄
郝俊松
张鹏
毛俊
张昱
王守开
郭春龙
Original Assignee
水木未来(北京)科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 水木未来(北京)科技有限公司 filed Critical 水木未来(北京)科技有限公司
Priority to PCT/CN2022/132928 priority Critical patent/WO2024103400A1/fr
Priority to PCT/CN2023/130796 priority patent/WO2024104250A1/fr
Publication of WO2024103400A1 publication Critical patent/WO2024103400A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/06—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • the present invention belongs to the field of pharmaceutical chemistry and relates to a compound used as a GPR75 activator, a pharmaceutical composition containing the compound, a preparation method thereof and medical uses thereof.
  • GPR75 G protein coupled receptor 75
  • G protein coupled receptor 75 is a member of the G protein coupled receptor family. Its endogenous agonist ligands include the metabolite 20HETE and the chemokine CCL5/RANTES6.
  • GPR75 is expressed in a large number of cell types. GPR75 expressed in pancreatic islets regulates insulin release through the activation of CCL5 and participates in regulating glucose homeostasis in the human body. GPR75 expressed in neurons prevents neuronal cell death mediated by amyloid ⁇ and human immunodeficiency virus viral proteins gp120 and Tat through the activation of CCL5. GPR75 expressed in the kidneys reduces glomerular protein permeability through 20-HETE activation.
  • GPR75 is a potential target for treating obesity, diabetes, high-consumption metabolic diseases caused by primary and malignant tumors, neurodegenerative diseases, kidney damage and other diseases, and has become a hot topic in the field of drug research and development.
  • the main agonists of GPR75 reported in the literature are 20-HETE and CCL5, both of which are endogenous ligands.
  • the 20-HETE molecule is extremely unstable and has a very short half-life, making it difficult to develop into a drug.
  • CCL5 is a polypeptide and also has the problem of poor drugability.
  • the downstream G protein signaling pathway and arrestin signaling pathway affect physiological and pathological processes after 20-HETE and CCL5 activate GPR75.
  • the object of the present invention is to provide a class of compounds with novel structures as GPR75 activators, pharmaceutical compositions containing the same, preparation methods thereof, and use thereof in the preparation of drugs for preventing or treating diseases regulated by GPR75.
  • the present invention provides a compound having a structure of formula (1) or a pharmaceutically acceptable form thereof:
  • W 1 , W 2 , W 3 and W 4 are each independently selected from CR 1 or N; provided that W 1 , W 2 , W 3 and W 4 are not N at the same time and there are no three consecutive N atoms;
  • X is selected from -OH or -NHR 2 ;
  • Y is selected from NH, O or S;
  • L 1 , L 2 , L 3 and L 4 are each independently selected from a bond, CR 4 R 5 , NR 3 , O or S, provided that L 1 , L 2 , L 3 and L 4 are not simultaneously a bond;
  • R4 and R5 are each independently selected from a bond, H, halogen, OH, SH, NH2 , CN, carboxyl, C1-6 alkyl, -OC1-6 alkyl, -SC1-6 alkyl, C3-8 cycloalkyl, 5-10 membered heterocycloalkyl, -OC3-8 cycloalkyl, -SC3-8 cycloalkyl, -NH( C1-6 alkyl), -N( C1-6 alkyl) 2 , -NH( C3-8 cycloalkyl), -NH(5-10 membered heterocycloalkyl), -N( C1-6 alkyl)( C3-8 cycloalkyl), -N( C1-6 alkyl)(5-10 membered heterocycloalkyl), -( C1-6 alkylene)-NH( C1-6 alkyl), -( C1-6 alkylene)-CONH( C1-6 alkyl), -( C1-6 alkylene)-NHCO( C1-6
  • the alkyl, alkylene, cycloalkyl, aryl, heteroaryl or heterocycloalkyl in R e is each optionally substituted with one or more substituents selected from halogen, OH, NH 2 , SH, ⁇ O, CN, carboxyl, —C 1-6 alkyl, —OC 1-6 alkyl, C 3-8 cycloalkyl, 5-10 membered heterocycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, —NH(C 1-6 alkyl), —N(C 1-6 alkyl) 2 , —NH(C 3-8 cycloalkyl), —NH(5-10 membered heterocycloalkyl), —N(C 1-6 alkyl)(C 3-8 cycloalkyl) or —N(C 1-6 alkyl)(5-10 membered heterocycloalkyl);
  • n is each independently selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8;
  • any two of L 1 , L 2 , L 3 and L 4 together with the atoms to which they are attached form a C 3-8 cycloalkyl, a 5-10 membered heterocycloalkyl, a C 6-10 aryl or a 5-10 membered heteroaryl, wherein each of the cycloalkyl, heterocycloalkyl, aryl or heteroaryl is optionally substituted with one or more R f ;
  • V is selected from 5-membered heteroaryl or -C ⁇ C-;
  • the pharmaceutically acceptable form is selected from pharmaceutically acceptable salts, esters, stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotopically labeled substances, metabolites or prodrugs.
  • each R 1 is independently selected from H, halogen, carboxyl, OH, CN, C 1-6 alkyl, C 3-8 cycloalkyl, -OC 3-8 cycloalkyl, -NR a R b , 5-10 membered heterocycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, -OC 1-6 alkyl, -C( ⁇ O)R a , -S( ⁇ O) 2 R a , -C( ⁇ O)NR a R b , -NR a C( ⁇ O)R b , -S( ⁇ O) 2 NR a R b , -NR a S( ⁇ O) 2 R b , -S( ⁇ O)( ⁇ NH)R a , -P( ⁇ O)R a R b , -P( ⁇ NH)R a R b , -P( ⁇ O)(OR a )(OR b
  • R 1 is each independently selected from H, F, Cl, Br, CN, -CH 3 or -OCH 3 .
  • R 2 and R 3 are each independently selected from H or -CH 3 .
  • X is selected from -OH or -NHCH 3 .
  • Y is selected from NH or O.
  • R 4 and R 5 are each independently selected from H, halogen, OH, SH, NH 2 , CN, carboxyl, C 1-6 alkyl, -OC 1-6 alkyl, -SC 1-6 alkyl, -NH(C 1-6 alkyl), -NH(C 3-8 cycloalkyl), -NH(5-10 membered heterocycloalkyl), -(C 1-6 alkylene)-NH(C 1-6 alkyl), -(C 1-6 alkylene)-CONH(C 1-6 alkyl), -(C 1-6 alkylene)-NHCO(C 1-6 alkyl), or -NHCO(C 1-6 alkyl); the alkyl, cycloalkyl, heterocycloalkyl are each optionally substituted with one or more Re ;
  • R 4 and R 5 are each independently selected from H, halogen, OH, SH, NH 2 , CN, carboxyl, C 1-6 alkyl, -OC 1-6 alkyl, -SC 1-6 alkyl, -NH(C 1-6 alkyl), -NH(5-10 membered heterocycloalkyl), -N(C 1-6 alkyl)(C 3-8 cycloalkyl), -N(C 1-6 alkyl)(5-10 membered heterocycloalkyl); said alkyl, cycloalkyl, heterocycloalkyl are each optionally substituted with one or more Re ;
  • R4 and R5 are each independently selected from H, -CH3 , -CH2OH- , -CH2CH ( CH3 ) 2 , - ( CH2 )mNH2, -( CH2 ) mSH , -( CH2 ) mSCH3 , - ( CH2 ) mNHCOCH3 , -(CH2)mNHSO2CH3, -(CH2 ) mNHSO2 ( CH2 ) 3 , -CH2NH ( CH2) 2N ( CH3 ) 2 , - ( CH2 )mNH( CH2COOH ) 2 , -CH2O ( CH2CH2O ) nCH2COOH , -CH2O ( CH2CH2O ) nCH2CH2OH, -CH2O ( CH2CH2O ) nCH2 CH 2 OCH 3 , -CH 2 NH(CH 2 CH 2 O) n CH 2 COOH, -(CH 2 )
  • Each n is independently selected from 0, 1, 2, 3, 4, 5, 6, 7 or 8
  • each m is independently selected from 1, 2, 3, 4, 5, 6, 7 or 8
  • each o is independently selected from 0, 1, 2 or 3.
  • R 4 and R 5 are each independently selected from H, CN, carboxyl or C 1-6 alkyl; the alkyl is optionally substituted with one or more substituents selected from halogen, OH, -NH 2 , CN or -NH-(C 1-6 alkylene)-N(C 1-6 alkyl) 2 .
  • R 4 and R 5 are each independently selected from H or C 1-6 alkyl; the alkyl is optionally substituted with one or more substituents selected from OH, -NH 2 or -NH-(C 1-3 alkylene)-N(C 1-3 alkyl) 2 .
  • R4 and R5 are each independently selected from H, -CH3 , -CH2OH-, -CH2CH ( CH3 ) 2 , -( CH2 ) 4NH2 , or -CH2NH ( CH2 ) 2N ( CH3 ) 2 .
  • R 4 and R 5 are taken together to form ⁇ O.
  • any two of L 1 , L 2 , L 3 and L 4 together with the atoms to which they are attached form a C 3-8 cycloalkyl, a 5-10 membered heterocycloalkyl, a C 6-10 aryl or a 5-10 membered heteroaryl, each of which is optionally substituted with one or more R f ;
  • L 1 and L 2 together with the atoms to which they are attached, form a C 3-8 cycloalkyl, a 5-10 membered heterocycloalkyl, a C 6-10 aryl, or a 5-10 membered heteroaryl, each of which is optionally substituted with one or more substituents selected from halogen, OH, -NH 2 , CN, -C 1-6 alkyl, -OC 1-6 alkyl, -SC 1-6 alkyl, -NH(C 1-6 alkyl), -N(C 1-6 alkyl) 2 , -NH-(C 1-6 alkylene)-NH 2 , -NH-(C 1-6 alkylene)-OH, or -NH-(C 1-6 alkylene)-N(C 1-6 alkyl) 2 .
  • L1 and L2 together with the atoms to which they are attached, form a C5-8 cycloalkyl, a 5-8 membered heterocycloalkyl, a phenyl, or a 5-10 membered heteroaryl, each of which is optionally substituted with one or more substituents selected from halogen, OH, -NH2 , CN, -C1-3 alkyl, -OC1-3 alkyl, -SC1-3 alkyl, -NH( C1-3 alkyl), -N( C1-3 alkyl ) 2 , -NH-( C1-3 alkylene) -NH2 , -NH-( C1-3 alkylene)-OH, or -NH-( C1-3 alkylene)-N( C1-3 alkyl) 2 .
  • substituents selected from halogen, OH, -NH2 , CN, -C1-3 alkyl, -OC1-3 alkyl, -SC1-3 alkyl, -NH( C1-3 alkyl
  • L 1 and L 2 together with the atoms to which they are attached, form a C 5-6 cycloalkyl, a 5-6 membered heterocycloalkyl, or a 6 membered heteroaryl, each of which is optionally substituted with one or more substituents selected from halogen, OH, -NH 2 , CN, -C 1-3 alkyl, -OC 1-3 alkyl, -SC 1-3 alkyl, -NH(C 1-3 alkyl), -N(C 1-3 alkyl) 2 , -NH-(C 1-3 alkylene)-NH 2 , -NH-(C 1-3 alkylene)-OH, or -NH-(C 1-3 alkylene)-N(C 1-3 alkyl) 2 .
  • L1 and L2 together with the atoms to which they are attached form a pyrimidinyl, pyridinyl, pyrazinyl, cyclohexyl, or tetrahydrofuranyl group, each of which is optionally substituted with one or more selected from -CH3 , -NHCH3 , -NH( CH2 ) 2N (CH3) 2 , -NH( CH2 ) 2NH2 , -NH( CH2 ) 2OH , -S( CH2 )2N( CH3 ) 2 , -S (CH2)2NH2, -S(CH2)2OH, -NH(CH2)3N(CH3)2 , -NH ( CH2 ) 3NH2 , -NH ( CH2 ) 3OH , -NH ( CH2 ) 3NHCOCH3 ⁇ -NH(CH 2 ) 2 NHSO 2 CH 3 ⁇ -NH(CH 2 ) 3 NHSO 2 CH 3 ⁇ -NH(CH 2
  • L 1 and L 2 together with the atoms to which they are attached form
  • L 1 and L 2 together with the atoms to which they are attached form
  • L2 and L3 together with the atoms to which they are attached form
  • V is selected from furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, or -C ⁇ C-.
  • V is selected from Or -C ⁇ C-.
  • Ar is selected from C 6-10 aryl or 5-8 membered heteroaryl, each of which is optionally substituted with one or more substituents selected from halogen, OH, NH 2 , CN, -C 1-3 alkyl, -OC 1-3 alkyl, -NH(C 1-3 alkyl) or -N(C 1-3 alkyl) 2 .
  • Ar is selected from phenyl or pyridinyl, each of which is optionally substituted with one or more substituents selected from F, Cl, Br, OH, NH2 , CN, -C1-3 alkyl, or -OC1-3 alkyl.
  • Ar is selected from phenyl or pyridinyl, each of which is optionally substituted with one or more substituents selected from F, Cl, Br, -CH 3 or -OCH 3 .
  • Ar is selected from
  • the compound represented by formula (1) of the present invention has a structure represented by formula (2):
  • W 5 , W 6 , W 7 and W 8 are each independently selected from CR 6 or N; provided that W 5 , W 6 , W 7 and W 8 are not N at the same time and there are no three consecutive N atoms;
  • R 6 is each independently selected from halogen, OH, -NH 2 , CN, -C 1-6 alkyl, -NH(C 1-6 alkyl), -N(C 1-6 alkyl) 2 , -NH-(C 1-6 alkylene)-NH 2 , -NH-(C 1-6 alkylene)-OH or -NH-(C 1-6 alkylene)-N(C 1-6 alkyl) 2 ;
  • Z is selected from O or S
  • U2 and U3 are independently selected from CH or N;
  • W 9 , W 10 , W 11 , W 12 and W 13 are each independently selected from CR 7 or N; provided that W 9 , W 10 , W 11 , W 12 and W 13 are not N at the same time and there are no three consecutive N atoms;
  • R 7 is each independently selected from halogen, OH, NH 2 , CN, carboxyl, -C 1-6 alkyl, -OC 1-6 alkyl, C 3-8 cycloalkyl, 5-10 membered heterocycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, -NH(C 1-6 alkyl), -NH(C 3-8 cycloalkyl), -NH(5-10 membered heterocycloalkyl), -N(C 1-6 alkyl)(C 3-8 cycloalkyl) or -N(C 1-6 alkyl)(5-10 membered heterocycloalkyl) or -N(C 1-6 alkyl) 2 ;
  • W 1 , W 2 , W 3 , W 4 and X are as defined in formula (1).
  • the compound represented by formula (1) of the present invention has a structure represented by formula (3):
  • Z is selected from O or S
  • U2 and U3 are independently selected from CH or N;
  • W 9 , W 10 , W 11 , W 12 and W 13 are each independently selected from CR 7 or N; provided that W 9 , W 10 , W 11 , W 12 and W 13 are not N at the same time and there are no three consecutive N atoms;
  • R 7 is each independently selected from halogen, OH, NH 2 , CN, carboxyl, -C 1-6 alkyl, -OC 1-6 alkyl, C 3-8 cycloalkyl, 5-10 membered heterocycloalkyl, C 6-10 aryl, 5-10 membered heteroaryl, -NH(C 1-6 alkyl), -NH(C 3-8 cycloalkyl), -NH(5-10 membered heterocycloalkyl), -N(C 1-6 alkyl)(C 3-8 cycloalkyl) or -N(C 1-6 alkyl)(5-10 membered heterocycloalkyl) or -N(C 1-6 alkyl) 2 ;
  • W 1 , W 2 , W 3 , W 4 , X, R 4 and R 5 are as defined in formula (1).
  • the compound represented by formula (1) of the present invention has a structure represented by formula (4):
  • W 1 , W 2 , W 3 , W 4 , R 6 , R 7 , U 2 and U 3 are as defined in formula (2).
  • the compound represented by formula (1) of the present invention has a structure represented by formula (5):
  • W 1 , W 2 , W 3 , W 4 , W 9 , W 10 , W 11 , W 12 , W 13 , R 4 , R 5 , U 2 and U 3 are as defined in formula (3).
  • the compound represented by formula (1) of the present invention has a structure represented by formula (6):
  • W 1 , W 2 , W 3 , W 4 , R 7 , U 2 and U 3 are as defined in formula (3).
  • the present invention also provides a compound or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, N-oxide, isotope label, metabolite or prodrug thereof, wherein the compound is selected from:
  • the compounds of the present invention may be prepared by any method known in the art. Reagents and starting materials are readily available to one of ordinary skill in the art. Individual isomers, enantiomers and diastereomers may be separated or resolved at any convenient point in the synthesis by methods such as selective crystallization techniques or chiral chromatography (See for example, J. Jacques, et al., “Enantiomers, Racemates, and Resolutions", John Wiley and Sons, Inc., 1981, and E. L. Eliel and S. H. Wilen).
  • the present invention provides a method for preparing a compound represented by formula (4), comprising:
  • step 1
  • the organic solvent in the above step (1-a) is selected from isopropanol, tert-butanol, dimethyl sulfoxide, or N,N-dimethylformamide; preferably isopropanol or N,N-dimethylformamide;
  • the base is selected from triethylamine, N,N-diisopropylethylamine, DBU, potassium carbonate, cesium carbonate, or sodium tert-butoxide; preferably triethylamine or N,N-diisopropylethylamine.
  • the organic solvent in the above step (1-b) is selected from dichloromethane, ethanol, acetonitrile, methanol, or tetrahydrofuran; preferably dichloromethane or ethanol; the reducing agent is selected from zinc powder or iron powder; preferably zinc powder; the acid is selected from acetic acid, ammonium chloride, dilute hydrochloric acid or trifluoroacetic acid; preferably acetic acid.
  • Step 2 Compound SMB and compound INT3-A react in the presence of an organic solvent, a base and a catalyst to obtain compound INT3;
  • the organic solvent in the above step 2 is selected from 1,4-dioxane/water, dimethyl sulfoxide, N,N-dimethylformamide, or toluene/water; preferably 1,4-dioxane/water;
  • the base is selected from potassium carbonate, cesium carbonate, sodium tert-butoxide, or potassium tert-butoxide; preferably potassium carbonate or cesium carbonate;
  • the catalyst is selected from Pd(PPh 3 ) 4 , Pd(dppf)Cl 2 , Pd(OAc) 2 or Pd 2 (dba) 3 ; preferably Pd(PPh 3 ) 4 or Pd 2 (dba) 3 .
  • the organic solvent in the above step (3-a) is selected from dichloromethane, ethyl acetate, tetrahydrofuran, acetonitrile, chloroform, or 1,2-dichloroethane; preferably dichloromethane or 1,2-dichloroethane;
  • the reducing agent is selected from sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride, lithium borohydride, or zinc borohydride; preferably sodium cyanoborohydride or sodium triacetoxyborohydride;
  • the catalyst is selected from titanium tetrachloride, tetraisopropyl titanate, bismuth trichloride, scandium trifluoromethanesulfonate, or anhydrous zinc chloride; preferably titanium tetrachloride or bismuth trichloride.
  • the base in the above step (3-b) is selected from lithium hydroxide, sodium hydroxide, or potassium hydroxide; preferably lithium hydroxide.
  • the present invention provides a method for preparing a compound represented by formula (5), comprising:
  • step 1
  • the organic solvent in the above step (1-a) is selected from N,N-dimethylformamide, dimethyl sulfoxide, N,N-dimethylformamide, acetonitrile, tetrahydrofuran, or dichloromethane; preferably N,N-dimethylformamide, tetrahydrofuran, or a mixed solvent of the two;
  • the base is selected from N,N-diisopropylethylamine, triethylamine; preferably N,N-diisopropylethylamine.
  • the deprotection conditions in the above step (1-b) are selected from methanol/acetyl chloride, HCl/methanol solution, HCl/1,4-dioxane solution, trifluoroacetic acid/dichloromethane, or methanol/methanesulfonic acid; preferably methanol/acetyl chloride, or trifluoroacetic acid/dichloromethane.
  • the organic solvent in the above step (2-a) is selected from N,N-dimethylformamide, acetonitrile, dichloromethane, or tetrahydrofuran; preferably N,N-dimethylformamide or dichloromethane;
  • the reducing agent is selected from sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride, lithium borohydride, zinc borohydride, or triethylsilane; preferably sodium cyanoborohydride or sodium triacetoxyborohydride.
  • the base in the above step (2-b) is selected from lithium hydroxide, sodium hydroxide, or potassium hydroxide; preferably lithium hydroxide.
  • W1 , W2 , W3 , W4 , R6 , R7 , W9 , W10 , W11 , W12 , W13 , R4 , R5 , U2 and U3 are as defined above.
  • one or more steps in the above-described preparation method may be omitted, and the order of the reaction steps may be appropriately adjusted as well as protection/deprotection reaction steps may be added or omitted as needed.
  • compositions preparations and kits
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising at least one of the above compounds or a pharmaceutically acceptable form thereof, and one or more pharmaceutically acceptable carriers, wherein the pharmaceutically acceptable form is selected from pharmaceutically acceptable salts, esters, stereoisomers, tautomers, polymorphs, solvates, N-oxides, isotope labels, metabolites or prodrugs.
  • a further object of the present invention is to provide a method for preparing the pharmaceutical composition of the present invention, which comprises combining at least one of the above compounds or a pharmaceutically acceptable form thereof or a mixture thereof with one or more pharmaceutically acceptable carriers.
  • Pharmaceutically acceptable carriers that can be used in the pharmaceutical compositions of the present invention include, but are not limited to, sterile liquids.
  • Pharmaceutically acceptable carriers include pharmaceutical excipients. Examples of suitable pharmaceutically acceptable carriers are described in Remington’s Pharmaceutical Sciences (2005).
  • the pharmaceutical composition can be administered in any form as long as it prevents, alleviates, prevents or cures the symptoms of a human or animal patient.
  • various suitable dosage forms can be prepared according to the administration route.
  • the pharmaceutical composition When administered orally, the pharmaceutical composition can be prepared into any oral acceptable preparation form.
  • the pharmaceutical composition When applied percutaneously or topically, the pharmaceutical composition may be formulated in a suitable ointment, lotion or liniment, wherein the active ingredient may be suspended or dissolved in one or more carriers.
  • the pharmaceutical composition can also be used in the form of injections, including injection solutions, sterile powders for injections and concentrated solutions for injections.
  • Another aspect of the present invention also relates to a pharmaceutical preparation comprising at least one of the above compounds, a pharmaceutically acceptable form thereof or a mixture thereof as an active ingredient, or a pharmaceutical composition of the present invention.
  • the preparation is in the form of a solid preparation, a semi-solid preparation, a liquid preparation or a gaseous preparation.
  • a further object of the present invention is to provide an article, for example, provided in the form of a kit.
  • Articles used herein are intended to include, but are not limited to, kits and packaging.
  • the article of the present invention comprises: (a) a first container; (b) a pharmaceutical composition located in the first container, wherein the composition comprises: a first therapeutic agent, including at least one of the above compounds or a pharmaceutically acceptable form thereof, or a mixture thereof; and (c) an optional package insert, which indicates that the pharmaceutical composition can be used to treat a disease or condition regulated by GPR75, for example: lipodystrophy, anorexia, diabetes, malignancy, glomerulonephritis, or a neurodegenerative disease (such as Alzheimer's disease).
  • a disease or condition regulated by GPR75 for example: lipodystrophy, anorexia, diabetes, malignancy, glomerulonephritis, or a neurodegenerative disease (such as Alzheimer's disease).
  • the package insert is a trademark, label, indicia, etc., which lists information related to the pharmaceutical composition located in the first container.
  • the listed information is generally determined by the regulatory agency (e.g., the U.S. Food and Drug Administration) that governs the region in which the product is to be sold.
  • the package insert specifically lists the indications for which the pharmaceutical composition is approved.
  • the package insert may be made of any material from which the information contained therein or thereon may be read.
  • the package insert is a printable material (e.g., paper, plastic, cardboard, foil, adhesive paper or plastic, etc.) on which the desired information may be formed (e.g., printed or applied).
  • Another object of the present invention is to provide a method for preventing or treating diseases or conditions regulated by GPR75, which comprises administering to an individual in need thereof an effective amount of at least one of the above-mentioned compounds or their pharmaceutically acceptable forms or mixtures thereof, or the pharmaceutical composition of the present invention.
  • the present invention provides the use of at least one of the above compounds or a pharmaceutically acceptable form thereof or the above pharmaceutical composition in the preparation of a medicament for preventing and/or treating a disease or condition modulated by GPR75.
  • the present invention provides at least one of the above compounds or a pharmaceutically acceptable form thereof or the above pharmaceutical composition for use in preventing and/or treating a disease or condition modulated by GPR75.
  • the disease or condition modulated by GPR75 includes, but is not limited to, lipodystrophy, anorexia, diabetes, malignancy, glomerulonephritis or a neurodegenerative disease (such as Alzheimer's disease).
  • the dosage regimen can be adjusted to provide the best desired response.
  • a single push, a bolus injection, and/or a continuous infusion, etc. can be administered.
  • several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the urgency of the treatment situation.
  • the dosage value may vary with the type and severity of the condition to be alleviated, and may include single or multiple doses.
  • the dosage of treatment varies, depending on considerations such as: the age, sex, and general health of the patient to be treated; the frequency of treatment and the nature of the desired effect; the degree of tissue damage; the duration of symptoms; and other variables that can be adjusted by individual physicians.
  • the specific dosage regimen should be adjusted over time according to individual needs and the professional judgment of the person administering the composition or supervising the administration of the composition.
  • the dosage and administration regimen of the pharmaceutical composition can be easily determined by a person of ordinary skill in the clinical field.
  • the composition or compound of the present invention can be administered 4 times a day to once every 3 days in divided doses, and the dosage can be, for example, 0.01 to 1000 mg/time.
  • the required dose may be administered in one or more doses to achieve the desired result.
  • the pharmaceutical composition according to the present invention may also be provided in unit dosage form.
  • each numerical range of a parameter disclosed herein should be understood to include each value and sub-range therein.
  • C 1-6 should be understood to include any sub-range and each point value therein, such as C 2-5 , C 3-4 , C 1-2 , C 1-3 , C 1-4 , C 1-5 , etc., as well as C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , etc.
  • 5-10 yuan should be understood as covering any sub-range and every point value therein, such as 5-7 yuan, 5-8 yuan, 5-9 yuan, 6-7 yuan, 6-8 yuan, 6-9 yuan, etc., as well as 5, 6, 7, 8, 9, 10 yuan, etc.
  • alkyl refers to a straight or branched saturated aliphatic hydrocarbon group.
  • C 1-6 alkyl used in the present invention refers to a saturated straight or branched hydrocarbon group having 1 to 6 carbon atoms (e.g., 1, 2, 3, 4, 5 or 6 carbon atoms).
  • C 1-6 alkyl can be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl or n-hexyl, etc.
  • alkylene refers to a saturated straight or branched divalent hydrocarbon group.
  • C 1-6 alkylene used herein refers to a saturated straight or branched divalent hydrocarbon group having 1 to 6 carbon atoms, such as methylene, ethylene, propylene or butylene.
  • cycloalkyl refers to a saturated or partially saturated, monocyclic or polycyclic (such as a bicyclic) non-aromatic hydrocarbon group; for example, a monocyclic ring such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclobutene, cyclopentene, cyclohexene; or a bicyclic ring, including a spirocyclic ring, a fused ring or a bridged ring (such as a bicyclo[1.1.1]pentyl, a bicyclo[2.2.1]heptyl, a bicyclo[3.2.1]octyl, a bicyclo[5.2.0]nonyl or a decahydronaphthyl group, etc.).
  • C3-8 cycloalkyl C3-8 cycl
  • heterocycloalkyl refers to a saturated or partially saturated, monocyclic or polycyclic (e.g., bicyclic) non-aromatic group having one or more carbon atoms (e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9) and one or more (e.g., 1, 2, 3, or 4) heteroatoms independently selected from N, O, P, and S in the ring.
  • the ring system in the heterocycloalkyl may be a fused ring, a bridged ring, or a spiro ring system. If the valence bond requirements are met, the heterocycloalkyl may be connected to other groups (or fragments) through any one of the carbon atoms or heteroatoms in the ring.
  • heterocycloalkyl group examples include oxirane, azetidinyl, oxetanyl, thietanyl, tetrahydrofuranyl, dioxolanyl, tetrahydrothiophenyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, morpholinyl, thiomorpholinyl, homopiperazinyl and the like.
  • aryl refers to an all-carbon monocyclic or fused polycyclic (eg, bicyclic) aromatic group having a conjugated ⁇ electron system.
  • C 6-10 aryl refers to an aromatic group containing 6 to 10 carbon atoms, such as phenyl or naphthyl.
  • heteroaryl refers to an aromatic group of a monocyclic or condensed ring with a conjugated ⁇ electron system, having one or more carbon atoms (such as 1, 2, 3, 4, 5, 6, 9 or 10 carbon atoms) and one or more (such as 1, 2, 3 or 4) heteroatoms independently selected from N, O, P and S in the ring.
  • Heteroaryl can be characterized by the number of ring atoms.
  • a 5-10 yuan heteroaryl can contain 5-10 (such as 5, 6, 7, 8, 9 or 10) ring atoms, particularly containing 5, 6, 9, 10 ring atoms.
  • heterocycloalkyl can be connected to the parent molecular part by any one of the ring atoms.
  • heteroaryl include thienyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, etc.
  • the term also encompasses the situation where the heteroaryl group can be optionally further fused to the aryl or heteroaryl ring to form a fused ring system.
  • halo or halogen group refers to F, Cl, Br or I.
  • substituent X and substituent Y are each independently hydrogen, halogen, hydroxyl, -CN, alkyl or aryl.
  • substituent Y can be either hydrogen, or halogen, hydroxyl, -CN, alkyl or aryl; similarly, when substituent Y is hydrogen, substituent X can be either hydrogen, or halogen, hydroxyl, -CN, alkyl or aryl.
  • substituted and its other variant forms in this article refer to one or more (such as 1, 2, 3 or 4) atoms or atomic groups (such as hydrogen atoms) on the specified atom being replaced by other equivalents, provided that the normal valence of the specified atom or atomic group in the current situation is not exceeded, and a stable compound can be formed. If a certain atom or atomic group is described as "optionally substituted by", it can be substituted or unsubstituted. Unless otherwise indicated, the attachment site of the substituent in this article can be from any suitable position of the substituent. When the connecting bond in the substituent is shown as a chemical bond between two atoms connected to each other in the ring system, it means that the substituent can be connected to any ring-forming atom in the ring system.
  • pharmaceutically acceptable salt refers to a salt of a compound of the present invention that is substantially non-toxic to an organism.
  • Pharmaceutically acceptable salts generally include (but are not limited to) salts formed by reacting a compound of the present invention with a pharmaceutically acceptable inorganic acid/organic acid/acidic amino acid or inorganic base/organic base/basic amino acid, which are also referred to as acid addition salts or base addition salts.
  • suitable salts see, for example, Jusiak, Soczewinski, et al., Remington’s Pharmaceutical Sciences [M], Mack Publishing Company, 2005 and Stahl, Wermuth, Handbook of Pharmaceutical Salts: Properties, Selection, and Use [M], Wiley-VCH, 2002. Methods for preparing pharmaceutically acceptable salts of the compounds of the present invention are known to those skilled in the art.
  • pharmaceutically acceptable ester refers to an ester which is substantially non-toxic to an organism and is hydrolyzed in vivo to form a compound of the present invention or a salt thereof.
  • the compound of the present invention itself may also be an ester.
  • isomers refers to compounds that have the same molecular weight because they have the same number of atoms and types of atoms, but differ in the arrangement or configuration of the atoms in space.
  • stereoisomer refers to a stable isomer that has a vertical asymmetric plane due to at least one chiral factor (including chiral center, chiral axis, chiral plane, etc.), thereby being able to rotate plane polarized light. Since the compounds of the present invention may have asymmetric centers and other chemical structures that may cause stereoisomerism, the present invention also includes these stereoisomers and mixtures thereof. Since the compounds of the present invention (or their pharmaceutically acceptable salts) include asymmetric carbon atoms, they can exist in the form of single stereoisomers, racemates, enantiomers, and mixtures of diastereomers.
  • these compounds can be prepared in the form of racemates. However, if desired, such compounds may be prepared or isolated as pure stereoisomers, i.e., single enantiomers or diastereomers, or mixtures enriched in a single stereoisomer (purity ⁇ 99%, ⁇ 98%, ⁇ 97%, ⁇ 96%, ⁇ 95%, ⁇ 90%, ⁇ 85%, ⁇ 80%, ⁇ 75%, ⁇ 70%, ⁇ 65%, or ⁇ 60%).
  • single stereoisomers of a compound may be prepared synthetically from optically active starting materials containing the desired chiral center, or by preparing a mixture of enantiomeric products followed by separation or resolution, e.g., conversion to a mixture of diastereomers followed by separation or recrystallization, chromatography, use of a chiral resolving agent, or direct separation of the enantiomers on a chiral chromatographic column.
  • Starting compounds of a particular stereochemistry may be either commercially available or prepared as described below and resolved by methods well known in the art.
  • the term "enantiomer" refers to a pair of stereoisomers that have non-superimposable mirror images of each other.
  • racemic mixture or “racemate” refers to a mixture containing equal parts of a single enantiomer (i.e., an equimolar mixture of two R and S enantiomers).
  • non-racemic mixture refers to a mixture containing unequal parts of a single enantiomer. Unless otherwise indicated, all stereoisomeric forms of the compounds of the present invention are within the scope of the present invention.
  • Solid wedge Virtual wedge To depict the covalent chemical bonds of the compounds of the invention.
  • all possible stereoisomers e.g., a specific enantiomer, a racemic mixture, etc.
  • stereoisomer shown is present.
  • stereoisomers of the compounds of the invention may encompass specific enantiomers, diastereomers, racemates, or mixtures thereof in any ratio.
  • tautomer refers to structural isomers with different energies that can be interconverted through a low energy barrier. If tautomerism is possible (such as in solution), a chemical equilibrium of tautomers can be achieved.
  • proton tautomers include (but are not limited to) interconversions through proton migration, such as keto-enol isomerization, imine-enamine isomerization, amide-imino alcohol isomerization, nitroso-oxime isomerization, etc. Unless otherwise indicated, all tautomeric forms of the compounds of the present invention are within the scope of the present invention.
  • polymorph refers to a solid crystalline form of a compound or complex.
  • the present invention encompasses all possible crystalline forms or polymorphs of the compounds of the present invention, which may be a single polymorph or a mixture of multiple polymorphs in any proportion.
  • solvate refers to a substance formed by a compound of the invention (or a pharmaceutically acceptable salt thereof) and at least one solvent molecule bound by non-covalent intermolecular forces.
  • the compounds of the invention may exist in the form of a solvate, which contains a polar solvent as a lattice structural element.
  • the amount of the polar solvent may be present in a stoichiometric ratio or a non-stoichiometric ratio.
  • isotope label refers to a derivative compound formed by replacing a specific atom in the compound of the present invention with its isotope atom.
  • the compound of the present invention includes various isotopes of H, C, N, O, F, P, S, and Cl, such as 2 H (D), 3 H (T), 13 C, 14 C, 13 N, 15 N, 17 O, 18 O, 18 F, 31 P, 32 P, 34 S, 35 S, 36 S, 37 Cl, and 125 I.
  • 12 C can be replaced by 13 C or 14 C
  • 1 H can be replaced by 2 H (D, deuterium) or 3 H (T, tritium)
  • 16 O can be replaced by 18 O, etc.
  • nitrogen-containing heterocycles can form N-oxides.
  • nitrogen-containing heterocycles that can form N-oxides.
  • tertiary amines can form N-oxides.
  • Synthetic methods for preparing N-oxides of heterocycles and tertiary amines are well known to those skilled in the art, including oxidation of heterocycles and tertiary amines with peroxyacids such as peracetic acid and metachloroperbenzoic acid (mCPBA), hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate and dioxirane such as dimethyl dioxirane.
  • peroxyacids such as peracetic acid and metachloroperbenzoic acid (mCPBA)
  • hydrogen peroxide alkyl hydroperoxides such as tert-butyl hydroperoxide
  • sodium perborate and dioxirane such as dimethyl dioxirane.
  • metabolite refers to a derivative compound formed after metabolism of a compound of the present invention, for example, produced by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, enzymatic hydrolysis, etc.
  • the present invention covers all possible metabolite forms of the compounds of the present invention, that is, substances formed in the body of an individual to whom the compounds of the present invention are administered.
  • the metabolites of the compounds can be identified by known techniques in the art, and their activity can be characterized by experiments.
  • prodrug refers to a derivative compound that can directly or indirectly provide a compound of the present invention after administration to an individual.
  • Particularly preferred derivative compounds or prodrugs are compounds that can increase the bioavailability of the compound of the present invention when administered to an individual (e.g., more easily absorbed into the blood), or compounds that promote the delivery of the parent compound to the site of action (e.g., the lymphatic system).
  • all prodrug forms of the compounds of the present invention are within the scope of the present invention, and various prodrug forms are known in the art, for example, see T. Higuchi, V. Stella, Pro-drugs as Novel Drug Delivery Systems [J], American Chemical Society, Vol. 14, 1975.
  • the present invention also covers compounds of the present invention containing protecting groups.
  • protecting groups In any process for preparing the compounds of the present invention, it may be necessary and/or desirable to protect sensitive groups or reactive groups on any related molecules, thereby forming a chemically protected form of the compounds of the present invention. This can be achieved by conventional protecting groups, such as those described in T. W. Greene, P. G. M. Wuts, Protective Groups in Organic Synthesis [M], John Wiley & Sons, 2006. These protecting groups can be removed at an appropriate subsequent stage using methods known in the art.
  • the present invention also encompasses methods for preparing the compounds described herein. It should be understood that the compounds of the present invention can be synthesized using the methods described below and synthetic methods known in the field of synthetic organic chemistry or variations thereof known to those skilled in the art. Preferred methods include (but are not limited to) those described below.
  • the reaction can be carried out in a solvent or solvent mixture suitable for the reagents and materials used and suitable for achieving the transformation.
  • active ingredient refers to a chemical entity that is effective in treating one or more symptoms of a target disorder or condition.
  • the term "effective amount” refers to the amount of active ingredient that, after administration, will achieve the desired effect to some extent, such as alleviating one or more symptoms of the condition being treated or preventing the occurrence of the condition or its symptoms.
  • prevention refers to inhibiting and delaying the onset of a disease, and includes not only prevention before the development of the disease but also prevention of recurrence of the disease after treatment.
  • “individual” includes human or non-human animals.
  • Exemplary human individuals include human individuals (referred to as patients) suffering from diseases (e.g., diseases described herein) or normal individuals.
  • Non-human animals in the present invention include all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock and/or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).
  • FIG1 shows the effects of compounds and 20-HETE on ERK phosphorylation levels.
  • MS Mass spectrometry
  • Nuclear magnetic resonance (NMR) measurements were performed using a Bruker nuclear magnetic resonance spectrometer, manufacturer: Bruker, model: AVANCE NEO HD-400.
  • the preparative high performance liquid chromatography (HPLC) method was performed using a Huachuang Meixi LC2060 preparative liquid chromatograph (Suyan technologies, ODS, HPLCONE 10C18A, 250*10mm*10um column & Suyan technologies, ODS, HPLCONE 10C18A, 250*30mm*10um column).
  • Thin layer chromatography purification was performed using Yantai Yinlong GF 254 (5-20 ⁇ m) silica gel plates.
  • the reaction is monitored by thin layer chromatography (TLC) or liquid chromatography-mass spectrometry (LC-MS), and the developing solvent system used includes but is not limited to: dichloromethane and methanol system, n-hexane and ethyl acetate system, and petroleum ether and ethyl acetate system.
  • the volume ratio of the solvent is adjusted according to the polarity of the compound, or adjusted by adding triethylamine, acetic acid or formic acid.
  • the eluent system includes but is not limited to the dichloromethane and methanol system and the petroleum ether and ethyl acetate system.
  • the volume ratio of the solvent is adjusted according to the polarity of the compound, and a small amount of triethylamine, acetic acid or formic acid can also be added for adjustment.
  • reaction temperature is room temperature (20°C to 30°C).
  • the reagents used in the examples were purchased from Acros Organics, Aldrich Chemical Company, Nanjing Yaoshi Technology, Titan Technology, Shanghai BiDe, Leyan, Anhui Zesheng or Beijing Inokai.
  • reaction solution was quenched with an aqueous solution of ammonium chloride (20 ml) under an ice bath, the aqueous phase was extracted with ethyl acetate (50 mL * 3), the combined organic phases were washed with an aqueous solution of sodium chloride (50 mL * 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was dried by spin drying.
  • N-Boc- ⁇ -amino acid (2.45 g, 14.01 mmol, 1 eq.) and SMA or SMC (10.78 mmol, 0.77 eq.) were dissolved in DMF (45 mL), and DIPEA (2.79 g, 21.55 mmol, 1.55 eq.) and HATU (6.15 g, 16.16 mmol, 1.15 eq.) were added. After stirring at room temperature for 1 hour, the mixture was heated to 45°C and reacted for 24 hours. LC-MS and TLC showed that the reaction was basically complete.
  • the intermediate 9 (0.19 mmol, 1 eq.) was dissolved in THF/MeOH (2 ml/2 ml), and an aqueous solution (1 ml) of lithium hydroxide (80 mg, 1.9 mmol, 10 eq.) was added dropwise. The reaction was stirred at room temperature for 6 hours. After the reaction was completed by TLC monitoring, the reaction solution was adjusted to pH ⁇ 3 with 1 M HCl solution, extracted with EA (20 mL*3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the filtrate was dried. The residue was separated by prep-HPLC (TFA condition, column: HPLCONE 10C18A 250*30mm*10um; Mobile Phase: [water(TFA)-ACN]: 10%-70%, 25 min) to obtain the target compound.
  • the intermediate 10 (0.19 mmol, 1 eq.) was dissolved in THF/MeOH (2 ml/2 ml), and an aqueous solution (1 ml) of lithium hydroxide (80 mg, 1.9 mmol, 10 eq.) was added dropwise. The temperature was raised to 50°C and stirred for reaction for 2 hours.
  • the intermediate 3-2 (77 mg, 0.32 mmol) was dissolved in ethanol (3.0 mL), sodium borohydride (18.12 mg, 0.48 mmol) was added under ice bath conditions, the temperature was slowly raised to room temperature, and the reaction was carried out for 2 hours. TLC showed that the reaction was complete. Under ice bath conditions, 5 mL of saturated sodium bicarbonate solution was added to quench the reaction, 10 mL of water was added to dilute, and ethyl acetate (15 mL*2) was extracted. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and dried under reduced pressure to obtain 73 mg of light yellow solid compound 21-1, with a yield of 94%.
  • N-tert-Butyloxycarbonyl acetaldehyde amine (100 mg, 0.54 mmol) was dissolved in anhydrous methanol (5 mL). At 0 ° C, 2-amino-5-chloro-benzoic acid methyl ester (103 mg, 0.65 mmol) and acetic acid (32 mg, 0.54 mmol) were added in sequence. After stirring at room temperature for 20 min, sodium cyanoborohydride (102 mg, 1.62 mmol) was added and stirred for 5 hours. LCMS showed that the reaction was basically complete. After the reaction solution was concentrated under reduced pressure, water (20 mL) was added, and ethyl acetate was extracted (20 mL*2).
  • LCMS (HCOOH): m/z 376.8(M+H).
  • the GTPase-Glo kit was used to detect the agonist activity of the compound on the GPR75 protein (the protein expression and purification method refers to the patent PCT/CN2022/117816 Test Example 1).
  • the experimental buffer was 20mM HEPES pH 7.5, 100mM NaCl, 0.01% MNG, 0.0006% CHS, 100 ⁇ M TCEP and 5mM MgCl 2.
  • the test compound and the control compound 20-HETE (a known GPR75 small molecule agonist) were diluted 10 times with 100% DMSO, and 4 concentration gradients were diluted continuously. The compound was then further diluted with buffer to 3 ⁇ working concentration, and 2.5 ⁇ L of the compound solution was added to the corresponding wells of the experimental plate.
  • the starting concentration of the test compound was 40 ⁇ M, the starting concentration of 20-HETE was 200 ⁇ M, and the working concentration of DMSO was 1%.
  • Dilute 1X GTPase-Glo and 5mM ADP with GTPase-Glo buffer add 7.5 ⁇ L of the solution to the test plate and incubate at room temperature. After 30 minutes, add 15 ⁇ L of detection reagent to the test plate and incubate at room temperature. Read the chemiluminescent signal on the BMG ClarioStar after 10 minutes.
  • %Effect 1-100%*(Signal-Bottom)/(Top-Bottom), where Signal represents the signal of the compound, Bottom represents the signal corresponding to 200 ⁇ M 20-HETE, and Top represents the signal of blank 1% DMSO.
  • CHO cells were diluted to 1.25 ⁇ 10 5 cells/ml using a double-antibody culture medium containing 88% DMEM, 10% FBS, 1% GlutaMax, and 1%, and 1 ml was inoculated into a 12-well plate per well.
  • the cells were cultured in a cell culture incubator at 5% CO 2 and 37°C for 24 hours. When the cells grew to 80%, the GPR75 plasmid transfection experiment could be performed.
  • Transfection reagent was prepared with Opti-MEM.
  • the total volume of transfection reagent per well in the 12-well plate was 250ul, including Opti-MEM, 200ng GPR75 plasmid, and 0.6ul Fugene HD (mass-volume ratio: 1:3), and the cells were allowed to stand at room temperature for 15min.
  • the old culture medium in the 12-well plate was removed, and the cells were washed with 1mL DPBS per well.
  • the DPBS was discarded and 1ml Opti-MEM culture medium was added.
  • 250ul transfection reagent was evenly added to each well. After gently shaking, the cells were placed in a cell culture incubator at 5% CO 2 and 37°C for 24h.
  • the compound of the present invention can activate GPR75, activate G protein and downstream pathways, and lead to an increase in the phosphorylation level of ERK.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé polycyclique utilisé en tant qu'activateur de GPR75, une composition pharmaceutique le comprenant, et son utilisation. Spécifiquement, la présente invention concerne un composé ayant une structure de formule (1) ou une forme pharmaceutiquement acceptable de celui-ci, une composition pharmaceutique le comprenant, son procédé de préparation et son utilisation dans la préparation d'un médicament pour la prévention ou le traitement d'une maladie régulée par GPR75.
PCT/CN2022/132928 2022-11-18 2022-11-18 Composé polycyclique utilisé en tant qu'activateur de gpr75, composition pharmaceutique le comprenant et son utilisation WO2024103400A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2022/132928 WO2024103400A1 (fr) 2022-11-18 2022-11-18 Composé polycyclique utilisé en tant qu'activateur de gpr75, composition pharmaceutique le comprenant et son utilisation
PCT/CN2023/130796 WO2024104250A1 (fr) 2022-11-18 2023-11-09 Composé polycyclique en tant qu'activateur de gpr75, composition pharmaceutique le comprenant et son utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2022/132928 WO2024103400A1 (fr) 2022-11-18 2022-11-18 Composé polycyclique utilisé en tant qu'activateur de gpr75, composition pharmaceutique le comprenant et son utilisation

Publications (1)

Publication Number Publication Date
WO2024103400A1 true WO2024103400A1 (fr) 2024-05-23

Family

ID=91083692

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2022/132928 WO2024103400A1 (fr) 2022-11-18 2022-11-18 Composé polycyclique utilisé en tant qu'activateur de gpr75, composition pharmaceutique le comprenant et son utilisation
PCT/CN2023/130796 WO2024104250A1 (fr) 2022-11-18 2023-11-09 Composé polycyclique en tant qu'activateur de gpr75, composition pharmaceutique le comprenant et son utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/130796 WO2024104250A1 (fr) 2022-11-18 2023-11-09 Composé polycyclique en tant qu'activateur de gpr75, composition pharmaceutique le comprenant et son utilisation

Country Status (1)

Country Link
WO (2) WO2024103400A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006135184A (ja) * 2004-11-08 2006-05-25 Fuji Photo Film Co Ltd 発光素子
US20200030291A1 (en) * 2016-03-09 2020-01-30 Board Of Regents, The University Of Texas System 20-hete receptor (gpr75) antagonists and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH645359A5 (de) * 1978-11-20 1984-09-28 Ciba Geigy Ag Lagerstabile, konzentrierte waessrige loesung von benzimidazolium-aufhellern.
DE69720773T2 (de) * 1996-12-23 2004-01-29 Bristol Myers Squibb Pharma Co SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER
MX2007003798A (es) * 2004-09-30 2007-04-23 Tibotec Pharm Ltd Pirimidinas 5-sustituidas con carbociclos o heterociclos inhibidoras del vih.
CN101220022B (zh) * 2007-11-23 2010-12-08 上海师范大学 2-(5-邻氯苯基-2-呋喃甲酰氨基)乙酰胺嘧啶衍生物及制备和应用
AU2009305624A1 (en) * 2008-10-17 2010-04-22 Exelixis, Inc. Sphingosine-1-phosphate receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006135184A (ja) * 2004-11-08 2006-05-25 Fuji Photo Film Co Ltd 発光素子
US20200030291A1 (en) * 2016-03-09 2020-01-30 Board Of Regents, The University Of Texas System 20-hete receptor (gpr75) antagonists and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE Registry 23 September 2014 (2014-09-23), ANONYMOUS: "Benzamide, 2-[[2-[[[5-(4-chlorophenyl)-2-oxazolyl]methyl]thio]-1- oxopropyl]amino]-N,6-dimethyl- (CA INDEX NAME)", XP093170594, retrieved from STNext Database accession no. 1624871-64-2 *
MURTAZA, B. ET AL.: "GPR75: An exciting new target in metabolic syndrome and related disorders", BIOCHIMIE, vol. 195, 16 January 2022 (2022-01-16), pages 19 - 26, XP086993906, DOI: 10.1016/j.biochi.2022.01.005 *
PASCALE, J.V. ET AL.: "Uncovering the signalling, structure and function of the 20-HETE-GPR75 pairing: Identifying the chemokine CCL5 as a negative regulator of GPR75", BR. J. PHARMACOL., vol. 178, 31 December 2021 (2021-12-31), pages 3813 - 3828, XP055843676, DOI: 10.1111/bph.15525 *

Also Published As

Publication number Publication date
WO2024104250A1 (fr) 2024-05-23

Similar Documents

Publication Publication Date Title
CA3078312A1 (fr) Composes chimiques
EP4382530A1 (fr) Inhibiteur de shp2, composition pharmaceutique le comprenant et son application
WO2023088441A1 (fr) Inhibiteur de kif18a
WO2019154364A1 (fr) Composé de pyrazine-2(1h)-cétone agissant en tant qu'inhibiteur de fgfr
CN102724975B (zh) IRE-1α抑制剂
CN116120296A (zh) 一种多环化合物、包含其的药物组合物、其制备方法及其用途
US11261170B2 (en) Aromatic compound, pharmaceutical composition and use thereof
EP3044223B1 (fr) Dérivés de 2,3-dihydro-1h-indén-1-one en tant qu'antagonistes du récepteur orphelin gamma apparenté au récepteur de l'acide rétinoïque (ror gamma) pour le traitement de la sclérose en plaques
JP6526064B2 (ja) ピリドピリミジンジオン誘導体
CN111630047A (zh) 含有羧酸基团的苯并氮杂环类化合物及其制备方法和用途
WO2024103400A1 (fr) Composé polycyclique utilisé en tant qu'activateur de gpr75, composition pharmaceutique le comprenant et son utilisation
WO2022007659A1 (fr) Immunomodulateur hétérocyclique
WO2020135454A1 (fr) Classe de composés stéroïdes et leur utilisation
WO2023165523A1 (fr) Dérivé méthoxy substitué par un cycle aromatique et son utilisation
WO2023160672A1 (fr) Composés et compositions pour le traitement d'états associés à l'activité du récepteur de lpa
CN115557913A (zh) 苯并氮杂环类化合物及其在药物中的应用
WO2021047406A1 (fr) Composé tricyclique, composition pharmaceutique le contenant, procédé de préparation correspondant et utilisation associée
WO2021169769A1 (fr) Composé aromatique et composition pharmaceutique et utilisation associées
WO2025016273A1 (fr) Dérivé d'isoquinoléine et composition pharmaceutique le comprenant, utilisations d'un dérivé d'isoquinoléine et d'une composition pharmaceutique
CN107973780B (zh) 一种取代的烯烃类化合物及其制备方法和用途
TW202448433A (zh) 作為α5-GABAA受體調節劑的雜環化合物及其用途
WO2025026392A1 (fr) Inhibiteur de kinésine kif18a et son utilisation
WO2024222660A1 (fr) Composé amide, composition pharmaceutique le comprenant et utilisation associée
CN118908937A (zh) 一种具有sting蛋白降解作用的化合物及其制备方法和用途
WO2024251133A1 (fr) COMPOSÉ HÉTÉROCYCLIQUE EN TANT QUE MODULATEUR DU RÉCEPTEUR α5-GABAA ET SON UTILISATION

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22965580

Country of ref document: EP

Kind code of ref document: A1